Arecor Limited has completed the dosing and all patient visits in phase I of its ultra-rapid acting insulin candidate, AT247.
The private pharmaceutical firm, which conducted the trial in Austria, said it expects preliminary results by the end of the year.
The product is designed to improve treatment for people living with Type I diabetes, by accelerating insulin absorption to manage more effectively blood glucose levels, especially after meals.
“The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster-acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes,” said chief executive Sarah Howell.
“I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”